Want to see TNON full AI Analyst Report?
TNON Stock Chart & Stats
$0.19
>-$0.01(-3.00%)
At close: 4:00 PM EDT
$0.19
>-$0.01(-3.00%)
Day’s Range― - ―
52-Week Range$4.38 - $54.95
Previous Close$0.19
Volume460.08K
Average Volume (3M)14.40M
Market Cap
$7.61M
Enterprise Value$11.30
Total Cash (Recent Filing)$1.68M
Total Debt (Recent Filing)$5.68M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Nov 18, 2026EPS Estimate
-5.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-46.30
Shares Outstanding667,047
10 Day Avg. Volume584,341
30 Day Avg. Volume14,400,925
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)1.78
P/FCF Ratio-0.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside5163.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-29.58
Revenue Forecast (FY)$6.59M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid growth in procedures and contributions from both Catamaran and SImmetry+ indicate improving product adoption. Sustained volume expansion could broaden the installed customer base and create a stronger foundation for future recurring procedure-driven revenue.
Gross Margin ExpansionThe margin improvement reflects better fixed-cost absorption, a streamlined commercial footprint and stronger field productivity. Higher gross margins can improve the economics of each procedure and provide operating leverage if revenue continues scaling.
Regulatory Clearance And Product PipelineFDA clearance supports continued commercialization of Catamaran and reclassifies certain instruments as reusable, potentially lowering procedure costs. Additional product launches and filings could strengthen differentiation and expand Tenon’s addressable clinical applications.
Bears Say
Persistent Operating LossesRevenue and gross profit growth have not yet translated into operating leverage because expenses remain high relative to the revenue base. Continued losses reduce financial flexibility and make profitability dependent on substantial further commercial scale.
Cash Burn And Balance-Sheet StrainNegative equity, meaningful debt and sustained cash consumption indicate that the business is not self-funding. This limits resilience, increases refinancing risk and may require additional equity or debt financing before operating cash flow improves.
Unproven Commercial AdoptionTenon’s revenue model depends heavily on surgeons adopting its systems and consistently performing SI joint procedures. Training seasonality, sales-force execution and distributor expansion create structural commercialization risk while the company remains relatively small.
Tenon Medical, Inc. News
TNON FAQ
What was Tenon Medical, Inc.’s price range in the past 12 months?
Tenon Medical, Inc. lowest stock price was $4.38 and its highest was $54.95 in the past 12 months.
What is Tenon Medical, Inc.’s market cap?
Tenon Medical, Inc.’s market cap is $7.61M.
When is Tenon Medical, Inc.’s upcoming earnings report date?
Tenon Medical, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 89 days.
How were Tenon Medical, Inc.’s earnings last quarter?
Tenon Medical, Inc. released its earnings results on Aug 13, 2026. The company reported -$12.35 earnings per share for the quarter, missing the consensus estimate of -$8.4 by -$3.95.
Is Tenon Medical, Inc. overvalued?
According to Wall Street analysts Tenon Medical, Inc.’s price is currently Undervalued.
Does Tenon Medical, Inc. pay dividends?
Tenon Medical, Inc. does not currently pay dividends.
What is Tenon Medical, Inc.’s EPS estimate?
Tenon Medical, Inc.’s EPS estimate is -5.26.
How many shares outstanding does Tenon Medical, Inc. have?
Tenon Medical, Inc. has 667,047 shares outstanding.
What happened to Tenon Medical, Inc.’s price movement after its last earnings report?
Tenon Medical, Inc. reported an EPS of -$12.35 in its last earnings report, missing expectations of -$8.4. Following the earnings report the stock price went down -13.423%.
Which hedge fund is a major shareholder of Tenon Medical, Inc.?
Currently, no hedge funds are holding shares in TNON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
TNON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong operational momentum with record second-quarter revenue, substantial gross profit and margin expansion, FDA clearance for Catamaran, an advancing R&D pipeline, and a $4.2M capital raise to extend runway. These positives are tempered by continued operating losses, higher operating expenses, non-cash interest expenses increasing net loss, and a diminished quarter-end cash balance. However, management has clear near-term catalysts (product launches, reusable instrumentation benefits beginning in Q3, training center momentum) that are likely to drive further progress.View all TNON earnings summariesTNON Stock 12 Month Forecast
Average Price Target
$10.00
▲(5163.16% Upside)
Technical Analysis
Strata Skin Sciences
―
Lifeward
―
enVVeno Medical
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Ownership Overview
10.70% Insiders
0.77% Mutual Funds
0.06% Other Institutional Investors
88.06% Public Companies and
Individual Investors